Kymera Therapeutics (KYMR) AGM 2026 summary

Opening remarks and agenda

• Chairperson welcomed attendees and introduced board members and executive officers present at the meeting.

• The independent registered public accounting firm, Ernst & Young, was introduced.

• The meeting agenda was outlined, referencing the Notice of Annual Meeting and Proxy Statement.

Board and executive committee updates

• Board members and executive officers were formally introduced, including roles such as Chief Legal Officer, Chief Medical Officer, Chief Business Officer, and Chief Financial Officer.

Shareholder proposals

• Proposal 1: Election of four Class III directors to serve until the 2029 annual meeting.

• Proposal 2: Non-binding advisory vote to approve named executive officer compensation.

• Proposal 3: Ratification of Ernst & Young as independent registered public accounting firm for fiscal year ending December 31, 2026.